In conclusion, considering that up to two-thirds of individuals with T2DM develop ASCVD in their lifetime, the results of this retrospective study highlight the utility of measuring PCSK9 in the context of a biomarker-based strategy of risk stratification. This evidence concerns the gene PCSK9 and atherosclerosis.